Clinical Trial Update: An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

An open-label Phase I study evaluating ASP5878, an oral FGFR1-4 inhibitor, in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ASP5878 (ASP5878)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED